Diabetes

ONWARDS Type 2 Diabetes (T2D) Clinical Trial Program Publications

The ONWARDS clinical trial program publications encompasses the phase 3 clinical trials evaluating the efficacy and safety of once weekly insulin icodec in adults with diabetes.

This page includes links to research published in peer-reviewed journals regarding Novo Nordisk-sponsored trials, including phase 3 trials conducted in patients with T2D. Novo Nordisk does not suggest or recommend the use of its products in any manner other than as described in it's FDA-required labeling, which can be accessed here.

ONWARDS 1

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Access Publication

View Resource

ONWARDS 2

Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial

Access

ONWARDS 3

Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial

Access

ONWARDS 4

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

Access

ONWARDS 5

Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5): A Randomized Trial.

Access

ONWARDS 9

Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial

Access

ONWARDS 10

Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Access

Post-Hoc Analysis of ONWARDS 2 and 4

Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.

Access

Discover more content or search Novo Nordisk Medical

Find more information

Find product information

Survey Novo Nordisk’s portfolio of products and resources for the treatment of diabetes, obesity, liver health, and cardiovascular disease and treatments for rare bleeding, rare endocrine, and rare renal disorders.

View products

Continuing education

Learn about accredited CE activities developed by third-party providers and supported by Novo Nordisk via independent medical education grants.

Explore CE

The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.

This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.

Top